Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

KU Medical Center to Lead $7.5 Million Male Contraceptive Research and Drug Development Program

Published: Thursday, April 12, 2007
Last Updated: Thursday, April 12, 2007
Bookmark and Share
The University will use the NIH grant to establish a multi-institutional organization that will work to develop new non-hormonal, reversible male contraceptive agents for drug production.

A researcher at the University of Kansas Medical Center has been awarded more than $7.5 million in funding from the National Institutes of Health to lead a team, including researchers at seven universities, in a collaborative effort to develop male contraceptives.

This five-year grant will establish the Interdisciplinary Center for Male Contraceptive Research and Drug Development, a multi-institutional organization that will work to develop new non-hormonal, reversible male contraceptive agents for drug production.

The center will not only consist of research teams at KU Medical Center and KU-Lawrence, but also collaborators across the country at the University of Minnesota, Duke University, the University of California-San Fransisco, Robert Wood Johnson Medical School, and the University of Medicine and Dentistry of New Jersey.

Funding for the center was awarded by the Contraception & Reproductive Health Branch of the National Institute of Child Health and Human Development.

The center will be directed by Joseph Tash, PhD, an associate professor of molecular and integrative physiology at KUMC, and associate director, Dr. Gunda Georg, Chair of Medicinal Chemistry at University of Minnesota. Tash, Georg, and a team of researchers at KUMC and KU Lawrence, have been conducting NIH-funded research, designing and testing male contraceptive agents, for more than five years.

Their work has lead to the development of some promising chemical compounds, such as Gamendazole, one of the most potent new oral anti-spermatogenic agents identified to date. Under this grant, research will continue on Gamendazole as well as exploring new lead compounds.

Tash said the group intends to take a multidisciplinary approach, focusing on several chemical compounds, and proteins that regulate testes function so that mature sperm are not produced. They are also concentrating on chemical agents that may temporarily deactivate enzymes so that sperm development is prevented or sperm are immobilized so the egg remains unfertilized. To identify new lead compounds, the center will utilize High Throughput Screening and proteomics to test hundreds of thousands of compounds.

While High Throughput Screening (HTS) technology is more common in private industry, KU is one of the few universities in the nation to have such a facility, which Tash said is important since many pharmaceutical companies have curtailed their research and development in male contraception. Without the HTS lab, screening hundreds of thousands of compounds could take years, but with the technology, screening time is dramatically reduced to weeks.

The research program in this center will go beyond identifying new protein targets involved in regulation of male fertility, and begin cutting edge drug discovery and design. The scientists involved in the research have a record of success in providing NIH with highly promising reversible non-hormonal male contraceptive agents.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Blocking Previously ‘Undruggable’ Cancer Protein
Researchers from the University of Kansas have found molecular that block previously ‘undruggable’ protein tied to cancer’s onset.
Monday, April 13, 2015
Scientific News
Promising Class of New Cancer Drugs Cause Memory Loss in Mice
New findings from The Rockefeller University suggest that the original version of BET inhibitors causes molecular changes in mouse neurons, and can lead to memory loss in mice that receive it.
Electrical Control of Cancer Cells
Research led by scientists at The University of Texas Health Science Center at Houston (UTHealth) has revealed a new electrical mechanism that can control these switches.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Inflammation Linked to Colon Cancer Metastasis
A new Arizona State University research study led by Biodesign Institute executive director Raymond DuBois has identified for the first time the details of how inflammation triggers colon cancer cells to spread to other organs, or metastasize.
Structural Discoveries Could Aid in Better Drug Design
Scientists have uncovered the structural details of how some proteins interact to turn two different signals into a single integrated output.
Determining the Age of Fingerprints
Watch the imprint of a tire track in soft mud, and it will slowly blur, the ridges of the pattern gradually flowing into the valleys. Researchers have tested the theory that a similar effect could be used to give forensic scientists a way to date fingerprints.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!